BMJ:利尿剂+ACEI+NSAID 当心急性肾损伤

2013-01-21 BMJ CMT 吴君德 整理

  一项加拿大研究显示,利尿剂、ACEI/血管紧张素受体阻滞剂(ARB)、非类固醇类抗炎药(NSAID)联用可增加急性肾损伤的风险。论文发表于《英国医学杂志》(BMJ 2013, 346:e8525)。   研究纳入了487372例降压药使用患者。中位随访5.9年,结果出现2215例急性肾损伤。同时使用利尿剂或ACEI/ARB联合NSAID并不升高急性肾损伤的发病率,而这三类


  一项加拿大研究显示,利尿剂、ACEI/血管紧张素受体阻滞剂(ARB)、非类固醇类抗炎药(NSAID)联用可增加急性肾损伤的风险。论文发表于《英国医学杂志》(BMJ 2013, 346:e8525)。

  研究纳入了487372例降压药使用患者。中位随访5.9年,结果出现2215例急性肾损伤。同时使用利尿剂或ACEI/ARB联合NSAID并不升高急性肾损伤的发病率,而这三类药物联用却使急性肾损伤的发病率升高[率比(RR)=1.31]。二次分析显示,在开始用药的30天内,发生急性肾损伤的风险最高(RR=1.82)。


Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study

Objectives 
To assess whether a double therapy combination consisting of diuretics, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers with addition of non-steroidal anti-inflammatory drugs (NSAIDs) and the triple therapy combination of two of the aforementioned antihypertensive drugs to which NSAIDs are added are associated with an increased risk of acute kidney injury.
Design 
Retrospective cohort study using nested case-control analysis.
Setting 
General practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database.
Participants 
A cohort of 487 372 users of antihypertensive drugs.
Main outcome measures 
Rate ratios with 95% confidence intervals of acute kidney injury associated with current use of double and triple therapy combinations of antihypertensive drugs with NSAIDs.
Results 
During a mean follow-up of 5.9 (SD 3.4) years, 2215 cases of acute kidney injury were identified (incidence rate 7/10 000 person years). Overall, current use of a double therapy combination containing either diuretics or angiotensin converting enzyme inhibitors or angiotensin receptor blockers with NSAIDs was not associated with an increased rate of acute kidney injury. In contrast, current use of a triple therapy combination was associated with an increased rate of acute kidney injury (rate ratio 1.31, 95% confidence interval 1.12 to 1.53). In secondary analyses, the highest risk was observed in the first 30 days of use (rate ratio 1.82, 1.35 to 2.46).
Conclusions 
A triple therapy combination consisting of diuretics with angiotensin converting enzyme inhibitors or angiotensin receptor blockers and NSAIDs was associated with an increased risk of acute kidney injury. The risk was greatest at the start of treatment. Although antihypertensive drugs have cardiovascular benefits, vigilance may be warranted when they are used concurrently with NSAIDs.    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
    2013-03-13 d830372
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
    2013-10-16 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
    2013-10-08 shanyongle
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
    2013-12-15 wjywjy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1793565, encodeId=175f1e9356532, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Mar 13 15:15:00 CST 2013, time=2013-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847487, encodeId=8d15184e48758, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Wed Oct 16 15:15:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655664, encodeId=8d0516556648a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 08 11:15:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033799, encodeId=4d1d2033e9937, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 15 20:15:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271919, encodeId=14f212e1919bf, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396745, encodeId=47f11396e4507, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413619, encodeId=562d1413619cc, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 23 06:15:00 CST 2013, time=2013-01-23, status=1, ipAttribution=)]
    2013-01-23 docwu2019

相关资讯

AHA2012:治疗急性心肾综合征超滤治疗不如药物治疗

  美国心脏协会(AHA)年会上公布的一项大型多中心随机研究显示,在利尿剂治疗有效的合并心肾综合征的急性失代偿性心力衰竭住院患者中,机械性静脉-静脉超滤的疗效不如药物治疗。   这项急性失代偿性心力衰竭心肾抢救研究(CARRESS-HF)由明尼阿波里斯市亨内平县医疗中心的Bradley A. Bart博士及其同事进行,共纳入188例利尿剂治疗有效的患者。患者被随机分成2组,一组接受阶梯式药物治疗

AHA 2012:治疗急性心肾综合征超滤治疗不如药物治疗

  美国心脏协会(AHA)年会上公布的一项大型多中心随机研究显示,在利尿剂治疗有效的合并心肾综合征的急性失代偿性心力衰竭住院患者中,机械性静脉-静脉超滤的疗效不如药物治疗。   这项急性失代偿性心力衰竭心肾抢救研究(CARRESS-HF)由明尼阿波里斯市亨内平县医疗中心的Bradley A. Bart博士及其同事进行,共纳入188例利尿剂治疗有效的患者。患者被随机分成2组,一组接受阶梯式药物治疗

Am Heart J:急性心衰初始推注利尿剂有益

  美国学者的一项研究表明,应用较大剂量利尿剂的急性心衰患者病情更为严重,并且可能从初始推注策略中获益。论文于2012年10月31日在线发表于《美国心脏杂志》(Am Heart J)。   DOSE-AHF研究共纳入308例入院24小时以内的急性心衰患者,并通过持续输注或推注方式随机给予大、小剂量静脉用利尿剂。此项研究以接受大(≥120 mg等量呋塞米,177例)、

PNAS:研究发现利尿剂新的治疗基因靶标

  近日,辛辛那提大学(UC)研究人员已经确定了利尿剂治疗那些如充血性心脏衰竭、肝硬化或肾功能衰竭患者新的治疗靶标。 这些结果发表在7月30日的PNAS期刊上,这可能会导致25年来第一个新的利尿剂治疗可以帮助利尿剂抵抗的患者。     Manoocher Soleimani医师说利尿剂的作用是增加尿量帮助患者处理自己多余的液体,因为他们的肾脏是无法做到的。在过去的几十年中,医生已使用

噻嗪类利尿剂存在显著效力差异

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血